Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

Max Augustin(University of Cologne), Philipp Schommers(University of Cologne), Melanie Stecher(University of Cologne), Felix Dewald(University of Cologne), Lutz Gieselmann(University of Cologne), Henning Gruell(University of Cologne), Carola Horn(University of Cologne), Kanika Vanshylla(University of Cologne), Veronica Di Cristanziano(University of Cologne), Luise Osebold(University of Cologne), Maria Roventa(University of Cologne), Toqeer Riaz(University of Cologne), Nikolai Tschernoster(University of Cologne), Janine Altmueller(University of Cologne), Léonard Rose(University Hospital Cologne), Susanne Salomon(University of Cologne), Vanessa Priesner(University of Cologne), Jan-Christoffer Lüers(University Hospital Cologne), Christian Albus(University Hospital Cologne), Stephan Rosenkranz(University Hospital Cologne), Birgit Gathof(University Hospital Cologne), Gerd Fätkenheuer(University of Cologne), Michael Hallek(University of Cologne), Florian Klein(University of Cologne), Isabelle Suárez(University of Cologne), Clara Lehmann(University of Cologne)
The Lancet Regional Health - Europe
May 18, 2021
Cited by 747Open Access
Full Text

Abstract

BACKGROUND: While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients. METHODS: 958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model. FINDINGS: We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms. INTERPRETATION: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19. FUNDING: COVIM:"NaFoUniMedCovid19"(FKZ: 01KX2021).


Related Papers

No related papers found

Powered by citation graph analysis